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Abstract
Cross-presentation is an important mechanism by which exogenous tumor antigens are presented
to elicit immunity. Since neutrophil elastase (NE) and proteinase-3 (P3) expression is increased in
myeloid leukemia, we investigated whether NE and P3 are cross-presented by dendritic cells (DC)
and B-cells, and whether the NE and P3 source determines immune outcomes. We show that NE
and P3 are elevated in leukemia patient serum and that levels correlate with remission status. We
demonstrate cellular uptake of NE and P3 into lysosomes, ubiquitination and proteasome
processing for cross-presentation. Using anti-PR1/HLA-A2 monoclonal antibody, we provide
direct evidence that B-cells cross-present soluble and leukemia-associated NE and P3, while DCs
cross-present only leukemia-associated NE and P3. Cross-presentation occurred at early time
points but was not associated with DC or B-cell activation, suggesting that NE and P3 cross-
presentation may favor tolerance. Furthermore, we show aberrant subcellular localization of NE
and P3 in leukemia blasts to compartments that share common elements of the classical MHC
class I antigen-presenting pathway, which may facilitate cross-presentation. Our data demonstrate
distinct mechanisms for cross-presentation of soluble and cell-associated NE and P3, which may
be valuable in understanding immunity to PR1 in leukemia.
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Introduction
Neutrophil elastase (NE) and proteinase 3 (P3) are serine proteases normally stored in the
azurophil granules of myeloid cells. They play a role in inflammation and anti-microbial
defenses,1, 2 and are known leukemia-associated antigens (LAA) from which PR1, the
human leukocyte antigen (HLA)-A2 restricted nonameric peptide, is derived.3, 4 PR1-
specific cytotoxic T lymphocytes (CTLs) were shown to preferentially kill leukemia cells
because of the high expression of NE and P3 by leukemia targets.4, 5 Clinical responses to
interferon-α2b, hematopoietic stem cell transplantation (HSCT), and PR1-peptide vaccine
have been correlated with circulating PR1-CTLs in patients with acute (AML) and chronic
(CML) myelogenous leukemia.4, 6–8 Since NE and P3 are aberrantly expressed by leukemia
and because the mechanisms involved in antigen presentation are critical for shaping
immune outcomes, we sought to investigate the mechanisms involved in NE and P3 cross-
presentation. Understanding these mechanisms is critical for understanding anti-leukemia
immunity and for further development of PR1-targeting immunotherapies.
Cross-presentation is a primary mechanism whereby exogenous antigens are presented by
antigen presenting cells (APCs)9 and is critical in eliciting antitumor immunity. Dendritic
cells (DCs) were shown to be efficient cross-presenting APCs.10, 11 B-cells are also effective
APCs, however, whether or not they can cross-present, the type of antigen that is favored for
B-cell cross-presentation, and whether B-cell cross-presentation leads to immune priming
(i.e. cross-priming) or tolerance (i.e. cross-tolerance) is not fully understood.12–14 Previous
cross-presentation studies have used tumor whole cell lysates (WCLs) that elicit polyclonal
T-cell responses or employed mouse models using the ovalbumin (ova)-derived peptide
SIINFEKL.15, 16 These models have been valuable to our understanding of cross-
presentation of tumor antigens, but have minimal direct clinical applicability. In this report,
we studied two proteins that have demonstrated clinical applicability in leukemia.
Since azurophil-granule proteins were shown to be elevated in serum from leukemia
patients,17 and since high-avidity PR1-CTLs are selectively deleted when exposed to P3
over-expressing CML,18 possibly due to cross-tolerance, we hypothesized that NE and P3
are cross-presented by APCs. Furthermore, we postulated that the source of antigen (soluble
vs. leukemia cell-associated), the cell type that mediates PR1 cross-presentation, and the
activation status of the APCs during PR1 cross-presentation determine the PR1 immune
response.
In this report, we first show that NE and P3 are elevated in serum from leukemia patients,
suggesting a source of soluble antigen, and show that their levels correlate with leukemia
remission status. We provide evidence that NE and P3 are taken up by APCs, localize to
lysosomes and are ubiquitinated, supporting the hypothesis that they are processed for cross-
presentation. Using 8F4, the novel mouse monoclonal antibody (mAb) that recognizes the
conformational epitope of PR1/HLA-A2,19 we show that PR1 is cross-presented by B-cells
from soluble and leukemia-associated NE and P3, while myeloid DCs (mDCs) cross-present
only leukemia-associated NE and P3. Cross-presentation occurred at early time points but
did not coincide with activation of mDCs or B-cells. We also show that NE and P3 in
leukemia blasts are mislocalized outside granules and are ubiquitinated, possibly facilitating
their cross-presentation. Lastly, we demonstrate that in the presence of co-stimulation, NE
and P3 cross-presentation leads to the proliferation of in vitro-expanded PR1-CTLs through
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proteasome dependent pathways. Overall, this study demonstrates that cross-presentation of
soluble and cell-associated NE and P3 involves distinct mechanisms, which may modulate
the anti-leukemia immune response to PR1.
Materials and methods
Patients, cells and cell lines
Patient and healthy donor (HD) samples were obtained after appropriate informed consent.
HMy2.CIR (B lymphoblast), KG-1 (dendritic-like cells), U-937 (myelomonoblastic
leukemia), HL-60 (acute promyelocytic leukemia) and T2 (B-cell/T-cell hybridoma) cell-
lines were obtained from ATCC (Manassas, VA, USA). HLA-A2*0201-transduced
HMy2.CIR, KG-1 and HL-60 cells were provided by Greg Lizee.20
B-cells were purified from HD peripheral blood (PB) mononuclear cells (PBMC) using
CD19+ MicroBeads (Miltenyi, Auburn, CA, USA) and maintained in complete media (CM)
supplemented with interleukin-4 (IL-4; 10 ng/mL; R&D Systems, Minneapolis, MN, USA)
and CD40 ligand (L) (500 ng/mL) with enhancer (E) (1 µg/mL; Alexis Biochemicals, San
Diego, CA, USA). Plasmacytoid DCs (pDCs) were purified using negative selection beads,
and purity was confirmed using CD-303 (Miltenyi). mDC were generated by plastic
adherence in tissue culture flasks and subsequent cultured in CM supplemented with
granulocyte-macrophage colony-stimulating factor (GM-CSF; 1000 U/mL) and IL-4 (500 U/
mL) (R&D) for 6 days. mDC were matured on day 6 with 50 ng/mL tumor necrosis factor-α
(TNF-α) and 0.1 µM prostaglandin E2 (Sigma, St. Louis, MO, USA) for 2 days.
Hematopoietic stem cells (HSC) were stained with antibodies targeting CD34, CD38 and the
lineage (lin) markers CD4, CD14, CD16 (all from Becton-Dickinson [BD], San Jose, CA,
USA) and CD19 (eBioscience, San Diego, CA,USA). CD34+, CD38−, lin−, HSCs were
sorted (Influx, BD) and stained for intracellular NE and P3.
Serum NE and P3 measurement
Serum samples were examined for NE using enzyme-linked immunosorbent assay (ELISA;
Cell Sciences, Canton, MA, USA). P3 ELISA was performed after coating microtitre plates
(Thermo-Scientific, Rochester, NY, USA) with purified goat anti-P3 polyclonal antibody
(Santa Cruz, Santa Cruz, CA, USA). Plates were blocked and serum samples were added
and incubated for 1 hour. Mouse anti-P3 mAb (NeoMarkers, Fremont, CA, USA) was added
and following a wash step, conjugated HRP-labeled goat anti-mouse IgG (Invitrogen,
Carlsbad, CA, USA) was added. 3,3’, 5,5’-tetramethylbenzidine solution was used as the
substrate and optical densities were read at 450 nm.
Cell pulsing for protein uptake and cross-presentation
To determine protein uptake, APCs were pulsed for 3 hours in serum-free medium
containing 5 µg/mL NE or P3. Cells were then analyzed by flow cytometry. To determine
cross-presentation, KG-1-A2 and HMy2.CIR-A2 cells were incubated with 5 µg/mL
purified NE or P3 for 6 and 18 hours, respectively. B-cells and mDCs were cultured for 6
hours with 5 µg/mL NE or P3, or with irradiated cells at a ratio of 1:1 (APC: irradiated-cell).
Fluorescent confocal microscopy and flow cytometry analysis
Directly conjugated fluorescent antibodies targeting the following antigens were used: NE
(Santa Cruz), P3 (NeoMarkers), lysosome-associated membrane protein-2 (LAMP-2;
eBioscience), HLA-A2, HLA-DR, CD11c, CD19, CD86, CD14 (all from BD); CD83
(Biolegend, San Diego, CA, USA), and anti-PR1/HLA-A2 (8F4).19 We used Alexa-647/488
kits (Invitrogen) to conjugate anti-NE, P3 and 8F4. Aqua live/dead stain (Invitrogen) was
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used to assess viability. Confocal imaging was performed using Leica Microsystems SP2 SE
confocal microscope (Illinois, USA) and analyzed using Leica LCS software (version 2.61).
Flow cytometry was performed using the Cytomation CyAn flow cytometer (Dako,
Carpinteria, CA, USA) and analyzed using FlowJo software (Tree Star Inc., Ashland, OR,
USA).
APC activation studies
B-cells and mDCs were cultured for 72 hours and 1.5 hours, respectively, with NE or P3
(5µg/mL), or irradiated cells at 1:1 APC to irradiated-cell ratio. CD40L (500 ng/mL)/E (1
µg/mL) and TNF-α (50 ng/mL) were used as positive controls for B-cells and mDCs,
respectively. Cells were stained for CD83 and HLA-DR an analyzed using flow cytometry.
Subcellular fractionation
Cytoplasmic, nuclear, membrane/membrane bound compartments (including granules,
endosomes, lysosomes, Golgi complex, and endoplasmic reticulum), and skeletal fractions
were generated using the ProteoExtract Subcellular Proteome Extraction kit (Calbiochem,
San Diego, CA, USA).21 Anti-calpain (Calbiochem), LAMP-2 (Protein Tech Group,
Chicago, IL, USA), nucleoporin-62 and GM-130 (both from BD) antibodies were used to
confirm the subcellular fractions.
Immunoprecipitation (IP) and immunoblot (IB) analysis
WCLs were generated by suspending cell pellets in lysis buffer (10 mM/L HEPES [pH 7.9],
10 mM/L KCl, 0.1 mM/L EGTA, 0.1 mM/L EDTA, and 1 mM/L DTT) containing protease
inhibitors and subsequent freeze-thaw cycles for 15 min. HMy2.CIR-A2 cells were pulsed
for 3 hours with NE- or P3-containing supernatant harvested from NE (ELA2)- or P3
(PRTN3)-transfected HMy2.CIR-A2 cells. For IP reactions, anti-ubiquitin antibodies (Santa
Cruz) were added to the pre-cleared WCLs and incubated overnight at 4°C. Subcellular
fractions, IP products and WCLs were separated by electrophoresis on 10% SDS gels,
transferred onto PVDF membranes and stained with anti-P3 (NeoMarkers) or anti-NE
antibodies (Santa Cruz). Chemiluminescence was captured on Kodak film. Densitometric
analysis was performed using Quantity One software (Bio-Rad, Hercules, CA, USA). The
percentage of total protein (% ProteinTotal) was calculated using the formula: %
ProteinTotal= Density Bandx/ Density BandTotal, where Density Bandx is the density of the
NE or P3 band from a subcellular fraction and Density BandTotal is the sum of the densities
of the NE or P3 bands in the 4 subcellular fraction from the same sample.
Expanding PR1-CTLs
HD HLA-A2+ PBMC were stimulated in vitro with PR1-peptide, as previously described.22
Briefly, T2 cells were incubated with 20 µg/mL of PR1 for 90 minutes at 37°C. Peptide-
loaded T2 cells were irradiated and cultured with freshly isolated PBMC (1:1 ratio) in CM
containing 10% human AB-serum. Re-stimulation with PR1-pulsed T2 cells was performed
on days 7, 14, and 21, and the following day 20 IU/mL of recombinant human interleukin-2
(rhIL-2; R&D) was added. On day 25, T-cells were harvested and tested for peptide-specific
proliferation.
Cell proliferation assay
PR1-CTLs were tested for cell proliferation using an ELISA assay to measure 5-
bromodeoxyuridine (BrDU) incorporation (Roche, Indianapolis, IN, USA). PR1-CTLs were
cultured with irradiated stimulator cells at a responder-to-stimulator ratio of 1:1 for 48
hours. HMy2.CIR cells were used as they lack endogenous NE and P3 and express the co-
stimulatory molecules B7.1 (CD80) and B7.2 (CD86).23 Stimulator cells included
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HMy2.CIR-A2 cells, ELA2- or PRTN3-transfected HMy2.CIR-A2 cells and HMy2.CIR-A2
or HMy2.CIR (HLA-A2-negative) cells that were cultured with NE- or P3-containing
supernatant from ELA2- or PRTN3-transfected HMy2.CIR cells. T2 cells were used alone
or pulsed with PR1 peptide (10 µg/mL). To inhibit Golgi and proteasome processing, we
added 1 µg/mL of brefeldin A (BFA; Sigma) or lactacystin (1–10 µg/mL; Calbiochem),
respectively.12 Incorporation of BrDU was determined by measuring absorbance (A) at 370
nm (reference, 492 nm). The stimulation index (SI) was calculated using the formula: SI =
(Aexperimental - Amedia)/(Acontrol - Amedia). Absorbance of PR1-CTLs from the unpulsed
HMy2.CIR-A2 cells was used as the control (Acontrol).
Statistical Analysis
We used GraphPad Prism 5.0 software (La Jolla, CA, USA) to perform the statistical
analyses and P-values <0.05 were used to establish significance.
Results
NE and P3 are elevated in leukemia patient serum
Since exogenous antigens are the protein source for cross-presentation, we used ELISA to
examine whether NE and P3 were higher in leukemia patient serum (Fig. 1). NE was
significantly higher in serum from patients with AML (median=1058 ng/mL; n=20) and
CML (median= 941.7 ng/mL; n=15), compared with HD serum (median= 65.3 ng/mL; n=5)
and AML patients in remission (median=257.9 ng/mL; n=17) (Fig. 1A). Similarly, P3 levels
were also significantly higher in serum from AML patients (median= 902.1 ng/mL; n=22)
compared with HD (median= 187.7 ng/mL; n=19) and patients in remission (median= 161.4
ng/mL; n=17) (Fig. 1B). Although CML patients had higher P3 levels (median=392.5 ng/
mL; n=15) versus HD, it did not reach significance (P=0.46). Intracellular cytokine flow
cytometry (CFC) assays showed poor PR1-CTL functions in patient with high NE and P3
levels (Supplementary Fig. 1 and Table 1). Furthermore, there was a correlation between
serum NE and P3 levels and disease burden in CML, but not in AML (Supplementary Table
2).
Soluble NE and P3 are taken up by APCs
We next sought to determine if soluble NE and P3 could be taken up by B-cells and DCs.
Although DCs are the principal cross-presenting cell type,11 we also examined B-cells since
they are often spared in myeloid leukemia and were shown to cross-present.12, 14, 24 We
used NE and P3 at 5 µg/mL, which approximates extracellular NE and P3 levels.25, 26 Using
flow cytometry, we demonstrated that HD APCs and the NE- and P3-deficient B-cell line
HMy2.CIR take up exogenous soluble NE and P3 (Fig. 2). Despite endogenous NE and P3
production,27, 28 mDCs took up exogenous NE and P3, thereby increasing their intracellular
levels.
NE and P3 localize within lysosomes and are ubiquitinated
Since protein ubiquitination and degradation by proteasome were implicated in antigen
presentation on major histocompatibility (MHC) class I,29–31 we examined the subcellular
localization and ubiquitination of NE and P3 following uptake. Confocal microscopy
showed that NE and P3 localized to LAMP-2-containing vesicles (i.e. lysosomes) following
uptake where proteins may be degraded into small peptides (Fig. 3A). Furthermore, we used
HMy2.CIR-A2 cells, which lack endogenous NE and P3, to demonstrate ubiquitination of
exogenous NE and P3 following uptake. After 3-hour pulsing with NE- or P3-containing
supernatant from ELA2- or PRTN3-transfected HMy2.CIR-A2 cells (Supplementary Fig. 2),
IP demonstrated ubiquitination of NE and P3 following uptake (Fig. 3B and C). Exogenous
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NE and P3 was also ubiquitinated by the ELA2- and PRTN3-transfected HMy2.CIR-A2
cells following uptake, as evidenced by stronger NE and P3 intensities in the lanes from the
pulsed/transfected cells. We also show that endogenous NE and P3 from the ELA2- or
PRTN3-transfected HMy2.CIR-A2 cells are ubiquitinated (Fig. 3B and C). Since
HMy2.CIR-A2 cells lack azurophil granules that normally store NE and P3, the localization
of NE and P3 in the cytosolic compartment of ELA2- or PRTN3-transfected HMy2.CIR-A2
cells may have facilitated ubiquitination. This further suggests that MHC-I pathway is
accessed by NE and P3, since cytosolic ubiquitination is important in MHC-I antigen
processing.31 Taken together, these results suggest that exogenous and cytosolic NE and P3
may be preferentially processed by the MHC-I pathway.
NE and P3 source affects cross-presentation by mDCs and B-cells
Having demonstrated uptake and ubiquitination of NE and P3, we next investigated whether
they are cross-presented in normal and leukemia APCs, the latter includes KG-1-A2 and
HMy2.CIR-A2.23, 32 Since HMy2.CIR-A2 cells lack endogenous NE, P3 and surface PR1/
HLA-A2, they are an ideal cell type for studying NE and P3 cross-presentation. KG-1-A2
and HMy2.CIR-A2 cell lines were cultured for 6 and 18 hours, respectively, with 5 µg/mL
NE or P3. These time points were selected as they provided maximal cross-presentation and
>90% cell viability. Additionally, cross-presentation by DC subsets was shown to occur at
early time points.33 After surface staining with 8F4,19 we detected increased PR1/HLA-A2
expression on the KG-1-A2 and HMy2.CIR-A2 (Fig. 4A). Since 8F4 binds PR1/HLA-A2, in
which the HLA-A2 molecule makes up a large portion of the conformational epitope,19, 34
8F4 antibody bound HLA-A2 on unpulsed cells. However, greater staining in pulsed cells
indicates PR1 cross-presentation.
Since DCs take up apoptotic and necrotic neutrophils,35 and because neutrophils and
myeloid leukemia cells express NE and P3 and have a high cell turnover, we investigated
whether cell-associated NE and P3 are a source for cross-presentation. Primary leukemia
and cell lines (HL-60 and U-937), as well as granulocytes, were irradiated and then co-
cultured with normal APCs for 6 hours. Our results showed that cross-presentation by
normal mDCs was significantly higher (P<0.05) when the NE and P3 source was irradiated
leukemia (Fig. 4B). In contrast, B-cells cross-presented soluble and leukemia-associated NE
and P3, but like mDCs, failed to cross-present NE and P3 from irradiated granulocytes (Fig.
4C). Results were similar irrespective of the HLA-A2 status of the irradiated cells,
indicating that PR1 is cross-presented from NE and P3, and not transferred from the surface
of the HLA-A2+ irradiated cells onto the APCs (data not shown).
NE and P3 are cross-presented but do not activate mDC or B-cells
Because up-regulation of co-stimulatory markers on APCs is necessary for eliciting immune
responses, we investigated the effects of NE and P3 source on APC surface expression of
CD83 and HLA-DR. Immature mDCs and B-cells were grown in CM in the presence of 5
µg/mL of soluble NE or P3, irradiated leukemia or normal granulocytes. Flow cytometry
showed that at early time points, coinciding with cross-presentation (90 minutes to 6 hours),
mDCs (CD11c+CD14−) significantly increased expression of CD83 after pulsing with
irradiated leukemia cells, but not after pulsing with soluble NE or P3, or granulocytes (Fig.
5A). Furthermore, soluble NE and P3 diminished TNF-α induced maturation. In addition,
there was no increase in mDC activation as measured by HLA-DR. Similar down-regulation
of mDC activation was previously reported following DC pulsing with apoptotic and
necrotic neutrophils.35 With respect to normal B-cells, none of the NE or P3 sources
activated normal B-cells as measured by surface staining for HLA-DR (Fig. 5B). We chose
the 72-hour time point because B-cell activation by CD40L/E (positive control) was not
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evident at earlier time points and furthermore, there was no B-cell activation by any of the
NE or P3 sources at earlier time points (data not shown).
NE and P3 in AML share common elements of the MHC-I antigen-presenting pathway
Cytosolic localization and ubiquitination of antigens facilitate their presentation on MHC-
I.9, 31 We demonstrated ubiquitination of cytosolic NE and P3 in U-937 cells and the ELA2-
and PRTN3-transfected HMy2.CIR cells (Fig. 3B and C) and previously reported higher
levels of PR1 on leukemia cells compared with granulocytes.19 Thus, we investigated
whether common elements of the MHC-I pathway are accessible to NE and P3 in primary
leukemia by virtue of their cytosolic localization and ubiquitination. To identify the location
of NE and P3 in granulocytes and leukemia blasts, we performed confocal microscopy and
found that NE and P3 were present diffusely in leukemia blasts indicating localization
outside the granules, in contrast with granulocytes where NE and P3 were within granules
(Fig. 6A). Furthermore, we detected extragranular NE and P3 in stem cells from HD and
leukemia patients (Fig. 6A).
To confirm extragranular localization of NE and P3, we performed IB on subcellular
fractions from normal granulocytes and leukemia blasts. Quantitative assessment showed
NE and P3 in all 4 fractions in the leukemia samples, in contrast to normal granulocytes
where they were primarily located in the granule-containing membrane fraction and nucleus
(Fig. 6B). IBs showed a significantly higher distribution of NE in cytosolic (20% vs. <1%),
nuclear (33% vs. 6%) and skeletal (24% vs. <1%) fractions in leukemia (P<0.05) (Fig. 6B).
The distribution of P3 was also higher in cytosolic (30% vs. <1%) and skeletal fractions
(22% vs. 2%) in leukemia (P<0.05) (Fig. 6B). As expected, the distribution of NE (94% vs.
23%) and P3 (71% vs. 23%) were higher in the granule fractions in granulocytes (P<0.05).
Table 1 shows the leukemia subtypes represented. We detected P3 in the nucleus of
granulocytes, similar to what was previously reported for NE (Fig. 6B).36, 37 Furthermore,
IB analysis of primary AML cells showed ubiquitinated NE and P3 in the cytosolic and
granule fractions (Fig. 6C), supporting our hypothesis that in leukemia, aberrant localization
of NE and P3 outside granules and ubiquitination may facilitate uptake and cross-
presentation by APCs.
NE and P3 are cross-presented through a proteasome-dependent pathway
To determine whether the proteasome and Golgi are involved in PR1 cross-presentation by
HMy2.CIR-A2 cells,12, 31, 38 which constitutively express the co-stimulatory molecules
CD80 and CD86,23 we used lactacystin and BFA to inhibit proteasome and antegrade Golgi
transporter, respectively. HMy2.CIR-A2 cells that were transfected with ELA2 or PRTN3
(Supplementary Fig. 2), or pulsed with NE or P3 containing supernatant caused increased
proliferation of PR1-CTLs compared with NE- or P3-pulsed HMy2.CIR-A2 cells to which
lactacystin or BFA were added (Figs. 7A, B). PR1-specific proliferation elicited by cross-
presentation of exogenously pulsed cells was similar to the proliferation induced by ELA2
and PRTN3 transfected HMy2.CIR-A2 and PR1-pulsed T2 cells. These data suggest that NE
and P3 are cross-presented via mechanisms involving proteasome and Golgi transport, since
both lactacystin and BFA treatment of HMy2.CIR-A2 inhibited PR1-CTL proliferation.
Discussion
Since PR1-targeted therapies for myeloid leukemia have shown efficacy,4–7 we investigated
factors that influence immunity to PR1. We show that in myeloid leukemia patients, serum
and leukemia-associated NE and P3 may be an antigen source for cross-presentation. B cells
and mDC cross-presented NE and P3 at early time points through mechanisms involving
endosomes and proteasomal processing. mDC cross-presented NE and P3 only from
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irradiated leukemia, while B cells cross-presented from both cellular and non-cellular
sources. Irrespective of antigen source, NE and P3 cross-presentation had no effect on
activation status of either APC. We also provide evidence that in myeloid leukemia blasts,
NE and P3 are ubiquitinated in extra-granular compartments, which can provide direct
access to MHC-I antigen presenting pathways and may facilitate cross-presentation of
leukemia-associated NE and P3. Finally as a clinical observation, we show that elevated
serum NE or P3 in leukemia patients, which may be cross-presented, are correlated with
dysfunctional PR1-CTLs.
Our data highlight the role of antigen source, co-stimulation and type of APC in determining
immunity to cross-presented antigens. Immunity following antigen cross-presentation has
been shown to be dependent on the viability of the cells providing the antigens. Spisek et
al15 showed that antigen cross-presentation from apoptotic leukemia blasts induced
leukemia immunity while Matheoud et al10 demonstrated immunity following DC cross-
presentation of antigens from live cells. Other studies have correlated cross-presentation of
apoptotic cells with tolerance and cross-presentation of necrotic cells with immune
priming.39, 40 These different outcomes were attributed to the cytokines produced by the
apoptotic cells and differential expression and activation of cell receptors and signaling
pathways in the apoptotic and effector cells.15, 40, 41 Our data clarifies some of these
discrepancies as we detected differences in the ability of mDC and B-cells to cross-present
based on the antigen source and also demonstrated variable effects of antigen source on
APC activation.
We show that cell-associated NE and P3 are more efficiently cross-presented by DCs. We
believe that this is because NE and P3 are ubiquitinated and located in leukemia cytoplasm
(Figs. 3b and 6), where they have access to MHC-I processing machinery42 and can undergo
proteasome dependent cross-presentation, supporting our original hypothesis that PR1 cross-
presentation may be facilitated by NE and P3 mislocalization in primary leukemia. The
actual protein sources of cell-associated NE and P3 used by APC for cross-presentation of
PR1 may be leukemia-associated ubiquitinated NE and P3 or NE and P3 peptides that are
cleaved by the leukemia that may be favored for further antigen processing by
proteasome.31, 43 Additionally, better antigen processing by DCs may be due to increased
antigen uptake of chaperone-rich cell (i.e. leukemia) lysates, which in addition to facilitating
antigen entry into the DC also prolong the protein half-life, two processes that are known to
facilitate cross-presentation.44–46
Whether B-cells are able to cross-present antigen remains controversial. Keller et al13
showed that B-cells failed to present exogenous antigen on MHC-I, while others have shown
that cross-presentation by B-cells elicits immune responses.47, 48 These conclusions about
cross-presentation by B-cells were complicated by use of exogenous factors such as gene
gun vaccination or CpG-DNA47, 48 that contribute to cell activation by stimulation of pattern
recognition receptors. In addition, the studies were conducted in vivo49 where it may be
difficult to discern cross-presentation from other cellular and molecular interactions that
determine immune outcomes. In contrast, we used in vitro methods to directly detect PR1
cross-presentation by B-cells using anti-PR1/HLA-A2. Thus, we were able to delineate the
relationship of peptide/HLA-A2 presentation vs. co-stimulatory molecule expression, a
difficult differentiation to make using functional assays as the sole measurement of cross-
presentation. Our results support the observation that B-cells can cross-present (Figs. 4 and
7). Because B-cells are not derived from malignant progenitor cells in myeloid leukemia,
they are often present in normal numbers,24 and therefore may play a significant role in NE
and P3 cross-presentation in leukemia. However, since exposure of B-cells to NE and P3 led
to PR1 cross-presentation in the absence of B-cell activation (Figs. 4 and 5), our data
suggest that B-cells may not play a role in the induction of PR1 immunity.
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While B-cells and DC showed no significant evidence of activation with cross-presentation
of NE or P3, PR1-CTLs were induced to proliferate by NE and P3 cross-presentation by
HMy2.CIR-A2 cells, which constitutively express the co-stimulatory molecules CD80 and
CD86.23 These results support a previous report that showed in vitro PR1-CTL expansion
using NE- and P3-loaded monocytes.50 However, in that study the monocytes/DCs that were
used to expand PR1-CTLs were cultured with GM-CSF, which up-regulates endogenous NE
and P351 and therefore confounds the distinction between endogenous NE/P3 presentation
and cross-presentation. Because we measured PR1/HLA-A2 surface expression on cells that
lack endogenous NE and P3 (i.e. HMy2.CIR-A2 and normal B cell), our results provide
direct evidence that PR1 is cross-presented from NE and P3 and in the setting of co-
stimulation, can induce a PR1-specific immune response. Taken as a whole, our results
suggest that eliciting in vitro immunity to PR1 may be enhanced by using leukemia cells as
the source of antigen, which can be taken up by both DC and B cells, and ensuring sustained
expression of co-stimulatory molecules by APCs. Such an approach could be utilized to
enhance PR1 immunity in stem cell grafts prior to their administration to patients, and may
be applicable to eliciting immunity to other LAAs. Moreover, since pulsing DCs directly
with peptides or leukemia lysates was shown to generate immunity against leukemia in DC
vaccine trials,15, 44, 52 our results expand on these prior reports by highlighting that
immunity to such antigens could be made even more potent by ensuring appropriate
sustained co-stimulation to accompany the cross-presentation of LAA by APCs.
Furthermore, the proliferation of PR1-CTL by P3-pulsed HMy2.CIR-A2 cells (Fig. 7) also
suggests that anti-leukemia immunity might be elicited in vivo with interventions to increase
and sustain PR1/HLA-A2 presentation coupled with treatments that maintain co-stimulation
by APCs. This is supported by a previous study showing that in patients with Wegener's
granulomatosis (WG), co-incubation of patient DC with P3 resulted in proliferation of
autologous P3-specific T cells, which are thought to mediate the autoimmune vasculitis in
WG.1 However, because PR1-CTL are deleted from the repertoire of leukemia patients,18
which confounds the direct effects of NE and P3 cross-presentation on PR1 immunity,
further in vivo validation of PR1 cross-tolerance mechanisms using animal models is
required.
Since we detected increased P3 and NE levels in leukemia patient serum and because
soluble P3 and NE can lead to PR1 cross-presentation by APCs without cell activation, our
data suggest that increased P3 and NE in myeloid leukemia may favor tolerance. Consistent
with this hypothesis, we observed a decreased functional response by PR1-CTL in AML
patients with elevated serum P3 or NE, compared with PR1-CTL from AML patients with
low serum P3 or NE levels (Supplementary Fig. 1 and Table 1). While soluble P3 and NE
correlated with disease burden in CML, which may lead to more tolerizing conditions
(Supplementary Table 2), the lack of correlation of soluble P3 or NE with disease burden in
AML suggests that there are additional mechanisms for facilitating tolerance conditions.
Aberrant subcellular localization of P3 and NE in both AML and CML suggests a role for
protein localization and cell turnover differences53, 54 in determining immune outcomes.
In summary, we provide direct evidence for cross-presentation of two clinically significant
human leukemia-associated self antigens, NE and P3, and show that antigen mislocalization
in leukemia critically affects antigen cross-presentation and possibly tumor susceptibility to
immune attack. Our observations may be relevant to other tumors since many tumor
antigens are derived from mislocalized self antigens. Further studies are under way to
investigate this possibility in non-hematologic malignant cells.
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Figure 1. NE and P3 are elevated in serum from patients with AML and CML
Serum from HD and patients with AML and CML was analyzed using ELISA. (A) NE level
was significantly higher in serum from AML (median= 1058 ng/mL; n = 20) and CML
(median= 941.7 ng/mL; n = 15) patients, compared with serum from HD (median= 65.3 ng/
mL; n = 5) and AML patients in remission (median= 257.9 ng/mL; n=17). (B) P3 level was
also significantly higher in serum from AML patients (median= 902.1 ng/mL; n=22)
compared with HD (median= 187.7 ng/mL; n=19) and patients in remission (median= 161.4
ng/mL; n=17).
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Figure 2. NE and P3 are taken up by APCs
HMy2.CIR cells and healthy donor APCs, including B-cells, pDCs and mDCs, were pulsed
with P3 (5 µg/mL) (top panel) or NE (5 µg/mL) (lower panel) for 3 hours, permeabilized
and stained with FITC-conjugated antibodies to NE and P3, and then analyzed using flow
cytometry. Unpulsed mDCs demonstrate baseline staining for NE and P3 as they
endogenously express both proteins.
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Figure 3. NE and P3 localize to lysosomal compartments and are ubiquitinated following uptake
(A) B-cells from healthy donors were enriched and pulsed with NE (5 µg/mL) or P3 (5 µg/
mL) for 4 hours. Cells were permeabilized and stained with FITC-conjugated anti-LAMP2
antibody (green) and Alexa-647-conjugated anti-NE or anti-P3 antibodies (red). Cells were
imaged using laser confocal microscopy, which shows localization of NE and P3 in
lysosomal compartments following pulsing. Results are representative of 2 separate
experiments from different healthy donors. (B) ELA2- and (C) PRTN3-transfected
HMy2.CIR-A2, as well as wild-type HMy2.CIR-A2 cells (lacking NE and P3), were
incubated for 3 hours with NE- or P3-containing supernatants that were harvested from the
ELA2- and PRTN3-transfected HMy2.CIR-A2 cells, respectively. Cell lysates were
immunoprecipitated with anti-ubiquitin and subsequently analyzed for NE (B) or P3 (C)
using immunoblotting. The leukemia cell line U-937 was used as a positive control for NE
and P3 ubiquitination. Ub indicates ubiquitin; IP, immunoprecipitation; and IB,
immunoblots.
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Figure 4. Leukemia, mDCs and B-cells cross-present soluble and cell-associated NE and P3
(A) A2-transfected KG-1 (KG-1-A2+) and -HMy2.CIR (HMy2.CIR A2+) leukemia cell
lines were pulsed with NE or P3 (5 µg/mL) for 6 and 18 hours, respectively. Cells were
stained with Alexa-647 conjugated 8F4 antibody and analyzed by flow cytometry. Results
show increased PR1 presentation following cell pulsing. Insets show no change in HLA-A2
expression following NE or P3 pulsing. Results are representative of 3 separate experiments.
(B) HLA-A2 positive normal mDCs or (C) B-cells were cultured with soluble NE (5 µg/
mL), P3 (5 µg/mL), or irradiated leukemia (n=4) or granulocytes (n=3) at a 1:1 APC to
irradiated-cell ratio for 6 hours. Cells were stained with Alexa-647-conjugated 8F4 antibody.
CD33, CD34, CD38, HLA-A2, aqua live/dead stain and light scatter were used to exclude
irradiated cells. CD19+ and CD11c+/CD14− were used to gate on B-cells and mDCs,
respectively. (A–C) Since 8F4 binds PR1/HLA-A2, in which the HLA-A2 molecule makes
up a large portion of the conformational epitope,19, 34 8F4 antibody bound HLA-A2 on
unpulsed cells. However, greater staining in pulsed cells indicates PR1 cross-presentation.
Results represent duplicate wells from 3 representative experiments. All data points are
expressed as mean fold-change ± SD in the MFI of 8F4 staining compared with unpulsed
cells. ANOVA followed by Tukey tests were performed using Prism 5.0 software
(*P<0.05).
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Figure 5. Effects of NE and P3 on activation of normal mDCs and B-cells
(A) Normal immature mDCs (CD11c+/CD14−) were cultured up to 6 hours with soluble NE
or P3 (5 µg/mL), irradiated leukemia or granulocytes at 1:1 DC to irradiated-cell ratio, or
with TNF-α (10 ng/mL) as a positive control. Cells were stained for CD83 or HLA-DR.
Results represent 5 experiments performed in duplicate. (B) Normal CD19+ B-cells were
enriched from healthy donor blood and cultured for 72 hours with NE or P3 (5 µg/mL),
irradiated leukemia or granulocytes at 1:1 B-cell to irradiated-cell ratio, or with CD40L (500
ng/mL)/E (1 µg/mL) as a positive control. Cells were then stained for HLA-DR. Results
represent 3 experiments performed in duplicate. All data points represent mean fold change
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± SD in MFI of CD83 or HLA-DR compared with unpulsed cells. ANOVA followed by
Tukey tests were performed using Prism 5.0 software (*P<0.05).
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Figure 6. Aberrant localization and ubiquitination of NE and P3 in myeloid leukemia
(A) Confocal microscopy showed NE and P3 confined to granules in normal granulocytes as
shown by distinct foci of fluorescence, and outside granules in AML blasts, as well as
leukemic and normal stem cells. NE and P3 (Alexa-488) appear green in primary AML and
healthy donor (HD) granulocytes. Because of their low frequencies, normal stem cells were
FACS sorted from 1 HD bone marrow and pooled with sorted stem cells from 5 GM–CSF
mobilized HD apheresis samples; sorted stem cells were also pooled from 7 different AML
samples. All stem cells were simultaneously co-stained with anti-NE Alexa-647 (red) and
anti-P3 Alexa-488 (green). DAPI blue was used to stain the nuclei. (B) Distribution of
intracellular NE and P3 as a percentage of total NE and P3. IB of subcellular fractions from
leukemia and granulocytes were analyzed by densitometry. Bars represent mean percent NE
or P3 distribution ± SD from leukemia (n=20) and normal granulocyte (n = 4) samples.
Two-tailed unpaired T-tests were used to compare the same fractions in healthy
granulocytes and leukemia (*P<0.05). (C) Representative IB of NE and P3 following
ubiquitin immunoprecipitation of representative AML patient sample. Subcellular fractions
were immunoprecipitated with anti-ubiquitin antibodies, and resolved on a 10%
polyacrylamide gel under reducing conditions. IB analysis for NE and P3 was subsequently
carried out. NE (0.5 µg) and P3 (0.5 µg) were used as positive controls for IB.
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Figure 7. Cross-presentation of PR1 by HMy2.CIR-A2 cells induces PR1-CTL proliferation
through proteasome- and Golgi-dependent mechanisms
Proliferation of PR1-CTL, measured by 48-hour BrDU uptake, was preferentially induced
by HMy2.CIR-A2 cells transfected with (A) ELA2 (ELA2-HMy2.CIR-A2) and (B) PRTN3
(PRTN3-HMy2.CIR-A2) and by non-transfected HMy2.CIR-A2 cells that were cultured
with (A) NE- or (B) P3-containing supernatant from ELA2-HMy2.CIR-A2 or PRTN3-
HMy2.CIR-A2 cells, respectively. Cross-presentation of NE and P3 were proteasome- and
Golgi-dependent, since it was abrogated by pretreatment of HMy2.CIR-A2 cells with
lactacystin (LAC) and brefeldin A (BFA). Negative controls included unpulsed HMy2.CIR-
A2, NE- or P3-pulsed HMy2.CIR cells (lacking HLA-A2), and unpulsed T2 cells. PR1-
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pulsed T2 cells were used as a positive control. Data represent the mean proliferation index
± SD of PR1-CTL in the experimental groups vs. PR1-CTL proliferation in control unpulsed
HMy2.CIR-A2 group from 2 representative experiments (*P< 0.01).
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